What We do


Flavocure Biotech, Inc. aims to be a leader in the transformation of the medicinal properties of natural products into new cures for mankind.

The company, in collaboration with some of the most prestigious research institutions in the world, have discovered ground-breaking molecules and generated preliminary data indicating activity against therapeutically validated kinase mutation targets. This led to the company’s success in achieving FDA orphan drug designation for their first drug, Creserol™ for the treatment of Acute Myeloid Leukemia (“AML”). Caflanone is the current lead molecule of Flavocure and received FDA Orphan Drug Designation in 2019 targeting pancreatic cancer. The company is committed to combating these diseases, along with Glioblastoma (an aggressive form of brain cancer).

Our R & D Platform


Focus on small molecules

Indication Area

Oncology (Hematological, Soft tissue & solid tumors)

Molecular Targets

- Kinases
- Epigenetics

Flavocure Biotech
Importance of Natural Products

Over half of all drugs introduced between 1940 and 2006 were of natural origin or inspired by natural compounds.

Timeline of major drug discoveries

Quinine – Malaria


Penicillin – Antibiotic




Vincristine – Cancer


Paclitaxel – Cancer


Artemisinin - Malaria

Oncology Pipeline

Acute Myeloid Leukemia (AML)

AML remains one of the few blood cancers in which no treatment progress has been made for decades and it remains an unmet area. The company has developed Creserol™, which has been granted Orphan Drug Designation status by the FDA. Flavocure collaborated with academic and industry research teams to further validate the effectiveness of Cresorol in the fight against AML.

Incidence and Mortality

Estimated new cases and deaths from AML in the United States in 2016 [1, 2] Number of New Cases and Deaths per 100,000: The number of new cases of acute myeloid leukemia was 4.1 per 100,000 men and women per year. The number of deaths was 2.8 per 100,000 men and women per year. These rates are age-adjusted and based on 2009-2013 cases and deaths.

Estimated New Cases in 2016 19,950
% of All New Cancer Cases 1.2%
Estimated Deaths in 2016 10,430
% of All Cancer Deaths 1.8%

1. SEER Stat Fact Sheets: Acute Myeloid Leukemia (AML), National Cancer Institute. http://seer.cancer.gov/statfacts/html/amyl.html
2. American Cancer Society: Cancer Facts and Figures 2016. Atlanta, Ga: American Cancer Society, 2016.

FLT3 as a therapeutic target in AML

  • AML is a heterogenous blood disorder
  • Mutations within the FMS-like Tyrosine Kinase 3 (FLT3) have been detected in up to 35% of AML patients
  • The Internal Tandem Duplication (ITD) is one of 2 activating FLT3 mutations identified and has been detected in 20-25% of AML patients with poor prognostic outcomes
  • Tyrosine Kinase Domain (TKD) is the second activating FLT3 mutation identified and includes FLT3-TKD-D835Y
  • The mutations cause activation of the FLT3 receptor & aberrant activation of downstream signaling pathways.
  • FLT3 mutations have been validated as therapeutic targets for AML
Research Pipeline

FBL-03G: Next Steps – Focus on Pancreatic Cancer

The company has expanded their research into Caflanone for pancreatic cancer, in collaboration with Harvard Medical School. The results of the Caflanone molecule have shown statistically significant results against Pancreatic cancer, in vivo. The company plans to continue their collaboration with Harvard Medical School in order to advance Caflanone towards an improved treatment and cure for pancreatic cancer.

Flavocure has plans underway for continued research and development:

STOPCAN Phase I/II Clinical Trial in Pancreatic Cancer Patients- Planned for Q1/Q2 of 2021
Cat Scan

Ultrasound guided placement of caflanone SRB fiducials in patients to start Q1 of 2021


Glioblastoma (GBM)

Glioblastoma (GBM) is the most common brain cancer of adults, and is among the most aggressive and deadly of all cancers. It accounts for more than 21% of all primary brain and CNS tumors.

Results from the preclinical testing of Caflanone has shown promise in the inhibition of Glioblastoma cancer. The company aims to develop a treatment for this form of cancer which currently has high morbidity rates. The annual incidence in the U.S. is 3 per 100,000 and is an incurable cancer with a median survival of 12 months from diagnosis. Despite decades of intensive surgical treatment, chemotherapy, radio-therapy, and tremendous basic science and clinical research focused on combating this cancer, the prognosis remains virtually unchanged. Most of the promising anticancer agents fail when it comes to GBM because they are unable to cross the blood-brain-barrier (BBB).

Colony-stimulating factor-1 receptor (CSF1R) inhibitors such as Caflanone targeting tumor-associated macrophages (TAM) have shown promise in mouse models of high-grade GBM. Caflanone is a small molecule that has been shown to cross the BBB.

News - Media

Press Releases

Flavocure Biotech Receives Orphan Drug Designation

Flavocure Biotech, Inc. recently accomplished a major milestone — receiving Orphan Drug designation from the US Food and Drug Administration for their drug caflanone being developed for the treatment of pancreatic cancer.

Pancreatic cancer is one of few orphan cancers for which survival has not improved substantially for more than 40 years.

Our Team

Board of Directors and Advisors

Dr. Henry L. C. Lowe, PhD
Executive Chairman

Dr. Henry Lowe, PhD. ,Director and Chairman, was educated at University of the West Indies, (B.Sc. Hons.), University of Sydney, (M.Sc.), Manchester University, (Ph.D.), Bolton Institute of Technology England, (Dip. Technical Education), Harvard University and M.I.T, U.S.A., (Post Doctoral Studies). Dr. Lowe served as Permanent Secretary for the Government of Jamaica, Dr. Lowe researched and established the first Ministry of Science & Environment in the CARICOM region. He served as Chairman as well as President & CEO of Blue Cross of Jamaica (including the Caribbean Islands). Dr. Lowe holds many awards and accolades, including the Jamaica Observer Business Leader Award (2006) and the CCRP Living Legend Award (2012); and is a member of the prestigious American Association for Cancer Research (AACR). Dr. Lowe is also a member of the American Association for the Advancement of Science, Fellow, Royal Society of Medicine United Kingdom, Harvard Medical School Postgraduate Association, American Association of Pharmaceutical Scientists and the American Chemical Society and a Life Member of the New York Academy of Sciences. Dr. Lowe is an Adjunct Professor in the Department of Medicine, University of Maryland School of Medicine, USA and Distinguished Adjunct Professor of Ethno-medicinal Chemistry, University of Technology, Jamaica. Dr. Lowe is widely published and has authored several books, over 40 peer reviewed scientific publications and has 12 patents and several pending patent applications.

Clark L. Swanson, MBA
Executive Vice Chairman

Mr. Swanson is Co-Founder and Executive Vice Chairman of Flavocure Biotech, Inc. a founding partner of the International Phytomedicines Institute at Harvard Medical School. A start-up veteran, Mr. Swanson has served as Co-Founder, President & Chief Executive Officer and Director of Blackline Safety Corp., a preeminent (Deloitte Fastest 500, TSX 50, Profit 500 & IDC Top 10 to Watch) technology company publicly traded on the Toronto Venture Exchange under the trading symbol: BLN. Under his leadership, he company grew to over 100 employees and a market capitalization of nearly $300,000,000. Prior to this, Mr. Swanson was a top revenue earner for several technology companies where he focused on life sciences at Amgen, DaVita, Pfizer and others.

Mr. Swanson holds a degree in Economics from Pepperdine University and a Masters in Business Administration from Graziadio School of Business & Management where he graduated with distinction. He is a guest lecturer at UCLA Anderson School of Management and Pepperdine Graziadio School of Business & Management.

Dr. Ngeh Toyang, PhD
(University of Leiden, Netherlands), Chief Executive Officer & Interim Chief Scientific Officer

Dr. Toyang has over 20 years of research experience in the field of pharmacognosy and drug development. He has worked at several prestigious research institutions including the National Center for Natural Products Research at the University of Mississippi School of Pharmacy, Natural Products Research Laboratory of the University of Leiden, The Netherlands and the Institute of Human Virology of the University of Maryland School of Medicine. Dr. Toyang is also the coordinator of the Flavocure and Dana Farber Cancer Institute, Harvard Medical School collaboration. He completed his PhD degree specializing in Pharmacognosy under the supervision of Prof. Dr. Rob Verpoorte at the University of Leiden, The Netherlands. Dr. Toyang is the author/co-author of over 30 peer reviewed scientific publications and a holder of 8 patents and several pending patent applications.

Dr. David Brooks, MD, PhD
Interim Chief Medical Officer

David C. Brooks has over 15 years of experience in drug development leading clinical and translational research. In particular, he has been the Medical Monitor for 7 First-In-Human clinical research This has led to a critical mass of experience in monitoring patient safety and pharmacovigilance. Dr. Brooks has overseen and/or led the 2 drugs that have been approved by the US FDA and are helping cancer patients every day. He has extensive experience preparing all the clinical and biomarker sections for 9 IND applications over the last 16 years. All of these clinical research projects have involved extremely close communication, coordination and collaboration with leading academic institutions throughout the USA and the biotechnology companies. He has specific experience planning and overseeing pancreatic adenocarcinoma clinical trials which led to the (very rare) successful approval of Abraxane for this tumor type. Dr. Brooks hold MD and PhD degrees from Cornell University. His experience with top pharma companies includes working with AstraZeneca as medical director.

Dr. Philip J. Fagan, Jr., M.D., F.A.C.E.P.

Dr. Philip J. Fagan, Jr., M.D., F.A.C.E.P., is currently medical director of CAN Emergency Physicians, California Hospitalists and Emergency Physicians and ER Physicians Medical Groups. The groups have expanded since 2015 and currently provide emergency medicine and hospital medicine services to seven hospitals in the greater Los Angeles area. Dr. Fagan has extensive emergency medicine and administrative experience. He is currently a Fellow of the American College of Emergency Physicians and has been certified and recertified at regular intervals by the Board of Emergency Medicine. He serves as Chief of Staff of a three-hospital group in Los Angeles. He has also served as Medical Director of McCormick Ambulance Services for twelve years.

Dr. Fagan is a graduate of the University of Notre Dame, Tulane University School of Medicine, with postgraduate studies at the University of Oregon Hospitals and Clinics. Dr. Fagan serves as an emeritus member of the Board of trustees of Tulane University. He also serves on the Library Council at the University of Notre Dame. Dr. Fagan has been chairman of the board of directors and served as Director of Mercury Air Group, a company listed on the American Stock Exchange now NYSE/American, from 1990 to 2000. As CEO of Emergency Department Physicians Medical Group, he practiced emergency medicine and was part of the administrative process. This group was acquired by TeamHealth, a Fortune 1000 Healthcare Provider.

Dr. Gary E. Swanson, M.D., D.A.B.R., F.R.C.P
Advisory Board Member

Dr. Swanson, M.D., D.A.B.R., F.R.C.P., served as the Chief of Medical Staff at Cold Lake Hospital and Medical Center after being Chairman of Radiology Consultants Associated (“RCA”). As a founding partner of RCA, Dr. Swanson grew the enterprise over three decades to become the largest Radiology practice in Western Canada providing service to the Peter Lougheed Hospital, Rockyview Hospital and twenty Diagnostic Imaging offices. Dr. Swanson also served as Director of the Alberta Medical Association and Chief Representative on Economics. He earned Fellowships fromThe Royal College of Physicians & Surgeons and the American Board of Radiology.

As an entrepreneur, Dr. Swanson was founder and Chairman of Goldcap, Inc. a publicly traded mining company, acquired by Argosy Minerals Inc.; Director of Bison Petroleum, Ltd. a publicly traded oil and gas company on the Toronto Stock Exchange; Director and Chairman of the Audit Committee for Imaging Dynamics, a Toronto Stock Exchange listed company focused on manufacturing and marketing state-of-the-art digital radiography systems. Dr. Swanson also served as a founding Director for Blackline Safety Corp, a TSX 50 company listed on the Toronto Venture Exchange.

Dr. Swanson is a published expert in the New York State Journal of Medicine and The American Journal of Roentgenology, Radium Therapy and Nuclear Medicine.

Dr. Swanson holds a Medical Doctorate from the University of Manitoba and specialized in Radiology at Cornell University in New York.

Dr. Jose Luis Calderon, M.D.
Advisory Board Member

Dr. Jose Luis Calderon, MD, Adjunct Associate Professor, Division of General Internal Medicine & Health Services Research, Department of Medicine, the David Geffen School of Medicine, UCLA, Clinical Research, and Adjunct Researcher for the Rand Corporation. He obtained a Doctorate of Medicine from Harvard Medical School and post-graduate training in Family Medicine (SUNY Health Sciences Center) and Neurology (New York University/Bellevue Hospital Center). Dr. Calderon, completed fellowship programs in epidemiology (Johns Hopkins School of Public Health), health literacy (AAMC Health Services Research Institute), and social equity/health disparities (Meharry College of Medicine/Vanderbilt University). Dr. Calderon is an expert pharmaco-epidemiology. Dr. Calderon is currently co-Director for the UCLA Center for Maximizing Outcomes and Research on Effectiveness (C-MORE).

Anthony Deasey
Chief Financial Officer

Mr. Deasey provides advisory services to start ups in the medical and technology sectors. He previously served as CEO, CFO and COO of public (Celsion Corp. and Northwest BioTherapeutics) and privately held (Seguro Surgical Inc.) Medtech companies, Tony has raised in excess of $100MM and successfully managed 2 exits. Prior to his migration into Medtech Tony was CFO of Church and Dwight Co Inc. (NYSE:CHD) Arm & Hammer), served as CFO of Rollerblade, owned by the Goldman Sachs and the Benneton Family, and World Kitchen Inc., a KKR Company, and had held increasingly senior positions at Unilever, Chesebrough Ponds and Price Waterhouse.

Thomas Lang, PhD
VP, Quality and Regulatory Affairs

An experienced pharmaceutical and biotech industry veteran, graduating with degrees in Chemistry and Pharmacy. Dr. Lang previously served as the President and Vice Chairman of Serono, Inc., a biopharmaceutical business of Merck, headquartered in Geneva, Switzerland.

Subscribe to Receive News from Flavocure Biotech




701 East Pratt Street

Baltimore, MD 21202